DARE

+ Watchlist + Portfolio

Dare Bioscience, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.84
52-Week Range: $0.69 – $3.78
Market Cap: $16.82M
P/E (TTM): —
EPS (TTM): -0.71
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -39.29%
Gross Margin: 243.91%
Operating Margin: -1582.53%
Profit Margin: 0.00%
Current Ratio: 0.99
Debt/Equity: —
Total Debt: $6.76M
Free Cash Flow: $-6.91M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $7.03M

DARE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$10.00M	$2.81M	$9.78K	$1.03M
Cost of Revenue	—	—	—	$295.80K
Gross Profit	—	—	—	$734.39K
Research & Development	$30.04M	$21.54M	$14.31M	$5.52M
Selling, General & Admin	$11.24M	$12.11M	$9.16M	$8.76M
Operating Expenses	$41.39M	$33.75M	$23.46M	$14.29M
Operating Income	-$31.39M	-$30.94M	-$23.45M	-$13.55M
EBITDA	-$31.36M	-$30.90M	-$23.41M	-$11.92M
Pretax Income	-$30.95M	-$30.16M	-$4.05M	-$13.40M
Net Income	-$30.95M	-$30.16M	-$4.05M	-$13.40M
Diluted EPS	-4.44	-4.15	-0.48	-1.20
Diluted Shares	7.05M	7.28M	8.50M	11.18M

DARE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.67M	$10.48M	$15.70M	$24.71M
Receivables	$1.70M	$949.21K	$229.98K	$573.06K
Current Assets	$43.04M	$17.54M	$18.45M	$27.06M
Total Assets	$43.83M	$21.28M	$22.10M	$32.47M
Current Liabilities	$31.62M	$20.48M	$21.61M	$23.69M
Total Debt	$488.74K	$1.40M	$1.30M	$2.66M
Total Liabilities	$32.71M	$26.33M	$28.11M	$29.63M
Retained Earnings	-$141.07M	-$171.24M	-$175.29M	-$188.69M
Shareholders' Equity	$11.11M	-$5.05M	-$6.01M	$2.84M
Working Capital	$11.41M	-$2.94M	-$3.17M	$3.38M

DARE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.09M	-$38.86M	$5.47M	-$9.89M
Capital Expenditure	-$63.07K	-$629.43K	-$573.05K	-$385.28K
Free Cash Flow	-$18.15M	-$39.49M	$4.90M	-$10.27M
Depreciation & Amortisation	$24.20K	$38.36K	$42.33K	$1.63M
Stock-Based Compensation	$2.16M	$2.53M	$2.20M	$1.50M
Investing Cash Flow	-$63.07K	-$629.43K	-$573.05K	-$385.28K
Financing Cash Flow	$1.34M	$15.64M	$354.52K	$19.28M
Net Change in Cash	-$16.81M	-$23.85M	$5.26M	$9.01M

DARE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$25.43K	-$21.17K	$2.26K	$1.02M	$152.46K	$187.55K
Cost of Revenue	$0.00	$0.00	$0.00	$295.80K	$242.32K	$319.89K
Gross Profit	$25.43K	-$21.17K	$2.26K	$727.88K	-$89.87K	-$132.34K
Research & Development	$2.30M	$1.43M	$1.18M	$622.04K	$660.46K	$241.97K
Selling, General & Admin	$2.31M	$2.38M	$2.50M	$1.58M	$2.25M	$2.59M
Operating Expenses	$4.61M	$3.81M	$3.67M	$2.20M	$2.91M	$2.84M
Operating Income	-$4.58M	-$3.83M	-$3.67M	-$1.47M	-$3.00M	-$2.97M
EBITDA	-$4.41M	-$3.37M	-$3.20M	-$936.87K	-$2.44M	-$2.40M
Pretax Income	-$4.38M	-$4.02M	-$3.56M	-$1.44M	-$3.00M	-$2.98M
Net Income	-$4.38M	-$4.02M	-$3.56M	-$1.44M	-$3.00M	-$2.98M
Diluted EPS	-0.50	-0.45	-0.28	—	-0.21	-0.20
Diluted Shares	8.76M	8.87M	12.76M	—	14.52M	14.89M

DARE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$10.33M	$5.04M	$23.08M	$24.71M	$18.52M	$12.62M
Receivables	$105.23K	$188.12K	$369.16K	$573.06K	$687.76K	$456.43K
Current Assets	$11.82M	$6.60M	$25.00M	$27.06M	$21.66M	$16.69M
Total Assets	$18.62M	$12.98M	$30.75M	$32.47M	$27.83M	$22.37M
Current Liabilities	$21.19M	$19.22M	$21.22M	$23.69M	$21.12M	$16.92M
Total Debt	$3.57M	$3.03M	$2.93M	$2.66M	$1.61M	$1.02M
Total Liabilities	$28.18M	$25.71M	$27.89M	$29.63M	$27.09M	$22.93M
Retained Earnings	-$179.67M	-$183.68M	-$187.25M	-$188.69M	-$191.69M	-$194.67M
Shareholders' Equity	-$9.56M	-$12.73M	$2.86M	$2.84M	$734.45K	-$560.10K
Working Capital	-$9.37M	-$12.62M	$3.79M	$3.38M	$540.12K	-$236.46K

DARE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.47M	-$5.42M	-$442.13K	$1.44M	-$5.52M	-$6.78M
Capital Expenditure	-$157.33K	—	-$174.70K	-$206.64K	—	—
Free Cash Flow	-$5.63M	-$5.26M	-$616.84K	$1.24M	-$5.52M	-$6.86M
Depreciation & Amortisation	$175.64K	$454.17K	$470.28K	$534.39K	$554.64K	$572.14K
Stock-Based Compensation	$377.36K	$359.02K	$403.03K	$357.16K	$455.06K	$286.60K
Investing Cash Flow	-$157.33K	$153.40K	-$174.70K	-$206.64K	$0.00	-$80.59K
Financing Cash Flow	$246.58K	-$43.79K	$18.65M	$424.13K	-$715.47K	$951.22K
Net Change in Cash	-$5.38M	-$5.31M	$18.03M	$1.66M	-$6.24M	-$5.90M

Market Snapshot

About

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative products for women's reproductive health. The company's pipeline includes product candidates for vaginal health, contraception, and fertility. Dare's lead programs address conditions such as bacterial vaginosis and include novel hormone therapies and non-hormonal contraceptive options. Based in San Diego, California, the company advances therapies designed to expand choices for women's health and address unmet medical needs.